Anzeige
Meldung des Tages: Insider kaufen kräftig zu – 421.670 CAD an Käufen, während Silber $88 erreicht

Promis Neurosciences News

Aktie
WKN:  A41MFQ ISIN:  CA74346M5054 US-Symbol:  PMN Branche:  Biotechnologie Land:  Kanada
17,59 $
-2,77 $
-13,61%
15,407 € 13.03.26
Depot/Watchlist
Marktkapitalisierung *
14,05 Mio. €
Streubesitz
56,99%
KGV
11,83
Index-Zuordnung
-

Promis Neurosciences News

01.12.25 - GlobeNewswire
ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310
Cross-​trial analysis supports plasma pTau as a potential early predictor of clinical benefit, reinforcing the biomarker-​driven design of ProMIS’ PRECISE-​AD trial
01.12.25 - GlobeNewswire
ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-​stage biotechnology company developing next-​generation ...
22.10.25 - GlobeNewswire
ProMIS Neurosciences Strengthens Board with Appointment of Slanix Paul Alex, Pharm.D., President and Portfolio Manager, Public Equity of Ally Bridge Group
Appointment reinforces ProMIS Neurosciences’ strategic vision and deepens investor engagement as the Company advances its differentiated Alzheimer’s program, PMN310
18.09.25 - PR Newswire
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
Anti-​Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics PR Newswire
18.09.25 - PR Newswire
Anti-Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics
Anti-​Aging Biotech Surges as $101M Competition Ignites Global Race Against Aging Demographics PR Newswire
03.09.25 - GlobeNewswire
ProMIS Neurosciences Receives DSMB Approval to Advance to Final Dose Escalation Cohort in Phase 1b Alzheimer’s Trial of PMN310
Cohort 2 fully enrolled; enrollment and dosing now underway for Cohort 3 (final dose level);
13.08.25 - GlobeNewswire
ProMIS Neurosciences Announces Second Quarter 2025 Financial Results & Corporate Highlights
U.S. FDA Grants Fast Track Designation for PMN310 in Alzheimer’s Disease, enhancing program’s potential for priority review
29.07.25 - GlobeNewswire
ProMIS Neurosciences to Showcase Protein-Misfolding Drug Discovery Platform & PRECISE-AD Trial Design at the 2025 Alzheimer’s Association International Conference
Presentation to highlight the Company’s proprietary protein-​misfolding platform, EpiSelect TM , used to develop PMN310
21.07.25 - GlobeNewswire
ProMIS Neurosciences Granted Fast Track Designation by U.S. FDA for PMN310 in the Treatment of Alzheimer’s Disease
FDA designation highlights the potential of PMN310 to deliver a more targeted approach to treating Alzheimer’s Disease

Newssuche

Videos

newspaper
13.03.26 -4,81%
Technical Trading: Kurzfristig Gold Long
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »